Abstract
The prophylactic efficacy of 17C91, a carbamate prodrug of atovaquone (ATQ), was investigated in a severe combined immunodeficient mouse model of Pneumocystis carinii pneumonia (PCP). At an oral dosage equivalent to 100 mg of ATQ per kg of body weight per day, 17C91 protected 9 of 10 mice from PCP and had a prophylactic efficacy comparable to that of co-trimoxazole (at 250 mg of sulfamethoxazole plus 50 mg of trimethoprim per kg per day orally). The intensity of P. carinii infection (infection score) of mice treated with 17C91 correlated with the concentration of ATQ in the plasma, with clearance of the infection associated with plasma ATQ levels of >35 micrograms/ml. 17C91 given orally provided enhanced levels of ATQ in the plasma compared with the conventional ATQ formulation. Additional studies reported in this paper demonstrate that the prophylactic activity of 17C91 against PCP in severe combined immunodeficient mice is comparable to that of a new oral microparticulate formulation of ATQ.
Full Text
The Full Text of this article is available as a PDF (177.2 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Comley J. C., Sterling A. M. Artificial infections of Pneumocystis carinii in the SCID mouse and their use in the in vivo evaluation of antipneumocystis drugs. J Eukaryot Microbiol. 1994 Nov-Dec;41(6):540–546. doi: 10.1111/j.1550-7408.1994.tb01514.x. [DOI] [PubMed] [Google Scholar]
- Comley J. C., Sterling A. M. Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice. Antimicrob Agents Chemother. 1995 Apr;39(4):806–811. doi: 10.1128/aac.39.4.806. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Falloon J., Kovacs J., Hughes W., O'Neill D., Polis M., Davey R. T., Jr, Rogers M., LaFon S., Feuerstein I., Lancaster D. A preliminary evaluation of 566C80 for the treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1991 Nov 28;325(22):1534–1538. doi: 10.1056/NEJM199111283252202. [DOI] [PubMed] [Google Scholar]
- Haile L. G., Flaherty J. F. Atovaquone: a review. Ann Pharmacother. 1993 Dec;27(12):1488–1494. doi: 10.1177/106002809302701215. [DOI] [PubMed] [Google Scholar]
- Hudson A. T. Atovaquone - a novel broad-spectrum anti-infective drug. Parasitol Today. 1993 Feb;9(2):66–68. doi: 10.1016/0169-4758(93)90040-m. [DOI] [PubMed] [Google Scholar]
- Hughes W. T. A new drug (566C80) for the treatment of Pneumocystis carinii pneumonia. Ann Intern Med. 1992 Jun 1;116(11):953–954. doi: 10.7326/0003-4819-116-11-953. [DOI] [PubMed] [Google Scholar]
- Hughes W. T., Gray V. L., Gutteridge W. E., Latter V. S., Pudney M. Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother. 1990 Feb;34(2):225–228. doi: 10.1128/aac.34.2.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hughes W., Leoung G., Kramer F., Bozzette S. A., Safrin S., Frame P., Clumeck N., Masur H., Lancaster D., Chan C. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med. 1993 May 27;328(21):1521–1527. doi: 10.1056/NEJM199305273282103. [DOI] [PubMed] [Google Scholar]